Earnings
Adaptive Biotechnologies Turns A Profit, Raises MRD Forecast To $276 Million-$286 Million
Third-quarter revenue fell 11% to $83.9 million on a missing Genentech payment, while clonoSEQ tests delivered rose 46%.
ADPT
Adaptive Biotechnologies (ADPT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Adaptive Asked Medicare's Contractor For A Five-Test Myeloma Maintenance Bundle, CEO Says
CEO Chad Robins said a $1,700 to $1,800 per-test price goal looks reachable, in some cases sooner, though he gave no guarantees on timing.
Earnings
Adaptive Biotechnologies Says CEO's Brother May Take A Role In Immune Medicine After Separation
Co-founder Harlan Robins could hold a meaningful role in the unit, which posted $11.3 million of third-quarter revenue.